Diagnostic Utility of CSF Tau and Aβ 42 in Dementia: A Meta-Analysis

CSF tau and Aβ42 are considered as important markers to diagnose Alzheimer's disease in early stages. Hence, it is important to assess their status in different types of dementia. The main objective of this study was to assess whether these CSF biomarkers can be used to make the differential diagnosis of AD. In the present study, articles published from 1998 till 2009 were taken and meta-analysis was performed to clarify the consistency in trends of biomarkers- CSF tau and Aβ 42 in AD and other dementias and whether the same can be used as diagnostic biomarkers for its early diagnosis. 11 out of 60 for CSF tau and 07 out of 40 for CSF Aβ 42, dementia case-control studies were selected for final analysis. Descriptive statistics shows that median effect size (raw mean difference) of CSF tau was 429 pg/mL (range: 32 to 910 pg/mL) in AD whereas in Dementia due to other causes (DOC) studies it was 69 pg/mL (range: −53 to 518 pg/mL). Similarly the median effect size of CSF Aβ 42 levels was −442 pg/mL (range: −652 to −41.200 pg/mL) whereas in DOC studies it was −193 pg/mL (range: −356 to −33 pg/mL).

[1]  E. Sinforiani,et al.  Cerebrospinal fluid levels of tau phosphorylated at threonine 181 in patients with Alzheimer’s disease and vascular dementia , 2008, Neurological Sciences.

[2]  Johannes Kornhuber,et al.  Blood‐based neurochemical diagnosis of vascular dementia: a pilot study , 2007, Journal of neurochemistry.

[3]  M. Verbeek,et al.  Cerebrospinal fluid amyloid beta42/phosphorylated tau ratio discriminates between Alzheimer's disease and vascular dementia. , 2006, The journals of gerontology. Series A, Biological sciences and medical sciences.

[4]  Tania B. Huedo-Medina,et al.  Assessing heterogeneity in meta-analysis: Q statistic or I2 index? , 2006, Psychological methods.

[5]  Jennifer Farmer,et al.  Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease , 2005, Annals of neurology.

[6]  R. Nitsch,et al.  Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42. , 2003, Archives of neurology.

[7]  J. Trojanowski,et al.  Biological markers for therapeutic trials in Alzheimer’s disease Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer’s disease , 2003, Neurobiology of Aging.

[8]  I. Zalonis,et al.  CSF tau protein and β‐amyloid (1–42) in Alzheimer's disease diagnosis: discrimination from normal ageing and other dementias in the Greek population , 2003, European journal of neurology.

[9]  Kaj Blennow,et al.  Cerebrospinal fluid levels of total‐tau, phospho‐tau and Aβ42 predicts development of Alzheimer's disease in patients with mild cognitive impairment , 2003 .

[10]  M. Verbeek,et al.  Brain-specific proteins in cerebrospinal fluid for the diagnosis of neurodegenerative diseases , 2003, Annals of clinical biochemistry.

[11]  K. Blennow,et al.  Decreased CSF-β-Amyloid 42 in Alzheimer’s Disease and Amyotrophic Lateral Sclerosis May Reflect Mismetabolism of β-Amyloid Induced by Disparate Mechanisms , 2002, Dementia and Geriatric Cognitive Disorders.

[12]  K. Blennow,et al.  Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. , 2001, Archives of neurology.

[13]  J. J. Visser,et al.  Genetic and biochemical markers for Alzheimer's disease: recent developments , 2000, Annals of clinical biochemistry.

[14]  K. Blennow,et al.  Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. , 1999, Archives of neurology.

[15]  P. Deyn,et al.  Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF , 1999, Neurology.

[16]  S. Hirai,et al.  Longitudinal study of cerebrospinal fluid levels of tau, Aβ1–40, and Aβ1–42(43) in Alzheimer's disease: A study in Japan , 1998 .

[17]  J. Kaye,et al.  High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. , 1998, Archives of neurology.

[18]  Giovanni B. Frisoni,et al.  Consensus report of the working group on: 'Molecular and biochemical markers of Alzheimer's disease' , 1998 .

[19]  K. Blennow,et al.  Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer’s disease: a community based follow up study , 1998, Journal of neurology, neurosurgery, and psychiatry.

[20]  H. Soininen,et al.  CSF tau is related to apolipoprotein E genotype in early Alzheimer's disease , 1998, Neurology.

[21]  S. Hirai,et al.  Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan. , 1998, Annals of neurology.

[22]  H. Soininen,et al.  The level of cerebrospinal fluid tau correlates with neurofibrillary tangles in Alzheimer's disease , 1997, Neuroreport.

[23]  J. Kornhuber,et al.  Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt–Jakob disease , 1997, Neuroscience Letters.

[24]  K. Blennow,et al.  Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? , 1995, Molecular and chemical neuropathology.

[25]  J. Trojanowski,et al.  Tau in cerebrospinal fluid: A potential diagnostic marker in Alzheimer's disease , 1995, Annals of neurology.

[26]  M. S. Patel,et al.  An introduction to meta-analysis. , 1989, Health Policy.